The number of novel, pivotal-stage projects in big pharma pipelines has noticeably dropped over the past couple of years, a recent Evaluate Vantage analysis found (Big pharma sports smallest late-stage pipeline for a decade, June 17, 2020). This raises a question: is this happening because developers are investing more in their success stories, and pursuing the so-called “pipeline in a project” approach?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,